Rein Therapeutics ( (RNTX) ) has released a notification of late filing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rein Therapeutics, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the fiscal year ending December 31, 2024. The delay is primarily due to the need for additional time to complete assessments of impairment losses on intangible assets. The company anticipates filing the report within 15 days of the original deadline. Financially, the company expects a significant impairment loss of approximately $37 million related to the delay in clinical development of its product candidate, LTI-01. Rein Therapeutics is committed to resolving these issues promptly, as indicated by the signature of Brian Windsor, Ph.D., President and CEO.
More about Rein Therapeutics
YTD Price Performance: -24.44%
Average Trading Volume: 61,828
Technical Sentiment Signal: Buy
Current Market Cap: $36.83M
Find detailed analytics on RNTX stock on TipRanks’ Stock Analysis page.